NDA 216513 · Medunik
Pheburane
Sodium Phenylbutyrate · Oral
OrphanLast checked: Nov 20, 2026Latest source record: Jul 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Jun 17, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
76
17 Phase 3, 5 recruiting
FAERS reports
177
122 serious, 46 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 17, 2026.
PHEBURANE is indicated as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients with urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS). Limitations of Use Episodes of acute hyperammonemia may occur in patients while on PHEBURANE. PHEBURANE is not indicated for the treatment of acute hyperammonemia, which can be a life-threatening medical emergency that requires rapid acting interventions to reduce plasma ammonia levels. PHEBURANE is a nitrogen-binding agent indicated as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients with urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS). ( 1 ) Limitations of Use PHEBURANE is not indicated for the treatment of acute hyperammonemia. ( 1 )
Mechanism: Sodium phenylbutyrate is a pro-drug and is metabolized to phenylacetate. Phenylacetate is a metabolically-active compound that conjugates with glutamine via acetylation to form phenylacetylglutamine. Phenylacetylglutamine is excreted by the kidneys, hence providing an alternate vehicle for waste nitrogen excretion.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 17, 2022 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLetterLabelReview
1 products under this application
- PHEBURANE · SODIUM PHENYLBUTYRATE 84GM/BOT · PELLETS, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Phenylbutyrate" as an intervention, any sponsor and status, largest first.
- Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis TreatmentPivotal-lookingStatus unknown
Amylyx Pharmaceuticals Inc.Industry
NCT05021536 · 664 participants · Start Oct 28, 2021 · Primary completion Jan 19, 2024
Drug: AMX0035 · For: Amyotrophic Lateral Sclerosis
Sites: Phoenix, Arizona; Los Angeles, California; Orange, California · 69 sites in all
- Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.Pivotal-lookingTerminated
TakedaTakeda (TAK)
NCT00759720 · 447 participants · Start Nov 2003 · Primary completion Dec 2004
Drug: TAK-559 and glyburide; TAK-559 and glyburide and 1 more · For: Diabetes Mellitus
- Immune Reconstitution in Tuberculosis DiseasePivotal-lookingCompleted
Karolinska InstitutetAcademic, hospital or other
NCT01698476 · 390 participants · Start Sep 2012 · Primary completion Aug 2015
Drug: vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate); Placebo tablets · For: Pulmonary Tuberculosis (TB)
Sites: Addis Ababa, Ethiopia
- Extension Study Evaluating The Safety And Tolerability of AMX0035Pivotal-lookingCompleted
Amylyx Pharmaceuticals Inc.Industry
NCT05619783 · 352 participants · Start Dec 29, 2022 · Primary completion Oct 16, 2024
Drug: AMX0035 · For: Amyotrophic Lateral Sclerosis
Sites: Leuven, Belgium; Bron, France; Clermont-Ferrand, France · 46 sites in all
- Study of TAK-559 in Treating Subjects With Type 2 Diabetes MellitusPivotal-lookingTerminated
TakedaTakeda (TAK)
NCT00762190 · 348 participants · Start Nov 2003 · Primary completion Dec 2004
Drug: TAK-559 and insulin; Insulin · For: Diabetes Mellitus
- Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes MellitusPivotal-lookingTerminated
TakedaTakeda (TAK)
NCT00762112 · 316 participants · Start Nov 2003 · Primary completion Dec 2004
Drug: TAK-559 · For: Diabetes Mellitus
- Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes MellitusPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00763022 · 302 participants · Start Nov 2003 · Primary completion Dec 2004
Drug: TAK-559; TAK-559 and 1 more · For: Diabetes Mellitus
- Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)Pivotal-lookingCompleted
International Centre for Diarrhoeal Disease Research, BangladeshAcademic, hospital or other
NCT01580007 · 288 participants · Start Dec 2010 · Primary completion Dec 2014
Drug: Active Sodium Phenylbutyrate and active cholecalciferol; Placebo Sodium Phenylbutyrate plus active cholecalciferol and 2 more · For: Pulmonary Tuberculosis
Sites: Dhaka, Bangladesh
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death24
- off label use21
- hyperammonaemia20
- nausea20
- diarrhoea18
- decreased appetite16
- ammonia increased13
- vomiting13
- product use complaint12
- retching12
- drug ineffective11
- fatigue10
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 5 |
| 2011 | 3 |
| 2012 | 15 |
| 2013 | 4 |
| 2014 | 6 |
| 2015 | 8 |
| 2016 | 8 |
| 2017 | 9 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 7 |
| 2022 | 10 |
| 2023 | 30 |
| 2024 | 24 |
| 2025 | 21 |
| 2026 | 10 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Pheburane (Sodium Phenylbutyrate)
2024 spending
$488K
Beneficiaries
n/a
15 claims
Per beneficiary
n/a
$26.70 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $487,856 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.
Paganoni S, Macklin EA, Hendrix S, et al. · N Engl J Med 2020 · Clinical Trial, Phase II, Multicenter Study
- Effect of sodium phenylbutyrate and taurursodiol on plasma concentrations of neuroinflammatory biomarkers in amyotrophic lateral sclerosis: results from the CENTAUR trial.
Bowser R, An J, Mehta L, et al. · J Neurol Neurosurg Psychiatry 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Intraindividual Comparisons to Determine Comparative Effectiveness: Their Relevance for G-BA's Health Technology Assessments.
Wagle JA, Flacke JP, Knoerzer D, et al. · Value Health 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Glutamine and hyperammonemic crises in patients with urea cycle disorders.
Lee B, Diaz GA, Rhead W, et al. · Mol Genet Metab 2016 · Clinical Trial, Research Support, N.I.H., Extramural
- Impact of sodium phenylbutyrate treatment in acute management of maple syrup urine disease attacks: a single-center experience.
Zubarioglu T, Dede E, Cigdem H, et al. · J Pediatr Endocrinol Metab 2021 · Clinical Trial
- Drug treatment for spinal muscular atrophy types II and III.
Wadman RI, van der Pol WL, Bosboom WM, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Medunik
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.